Bradley J. Monk, MD
Profesor and Division Director
University of Arizona Cancer Center
Division of Gynecologic Oncology
500 W. Thomas Road, Suite 600
Phoenix,
AZ
USA
85013
Biographical Sketch: Dr. Monk is currently Professor and Director in the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, AZ. Dr. Monk is also a Professor on the Clinical Scholar Track at the University of Arizona College of Medicine – Phoenix. Dr. Monk’s research interests include chemotherapy to treat ovarian and cervical carcinoma; the etiology, biomarkers in gynecologic cancers; and quality of life in women with advanced ovarian cancer. He is on the Board of Directors for the Gynecologic Oncology Group (GOG) and is the Group’s Cervical and Vulvar Committee Chair. Additionally, Dr. Monk is an investigator for the GOG and also a member of the Publications committee, Protocol Development committee and Immunotherapy subcommittee. Dr. Monk is a fellow of the American College of Surgeons, the American College of Obstetricians and Gynecologists and the American Society for Colposcopy and Cervical Pathology, as well as being an active member of the Society of Gynecologic Oncologists, the American Society of Clinical Oncology and the American Association for Cancer Research and other professional organizations. He is a current member of the editorial boards of several journals, including Gynecologic Oncology and Clinical Ovarian Cancer, and a reviewer for journals including Clinical Cancer Research, Obstetrics and Gynecology, Cancer and Journal of Clinical Oncology. Dr. Monk has authored more than 175 peer-reviewed articles along with 26 book chapters dealing predominantly with the prevention and chemotherapy of gynecologic malignancies and patient quality of life."
Papers:
9
Differences in presentation and survival of Asians versus Caucasians with ovarian cancer: a Gynecologic Oncology Group ancillary study of 7,914 patients
24
Impact of circulating tumor cells (CTCs) on overall survival among patients treated with chemotherapy plus bevacizumab for advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
57
Impact of treatment-induced neutropenia and thrombocytopenia on survival in patients with advanced ovarian cancer treated with chemotherapy plus bevacizumab: an NRG Oncology/Gynecologic Oncology Group ancillary data study
62
Complete responses in the irradiated field following treatment with chemotherapy with and without bevacizumab in advanced cervical cancer: an NRG Oncology/Gynecologic Oncology Group study
73
Chemotherapy toxicity and quality of life in older women with advanced or recurrent endometrial cancer: an NRG Oncology – Gynecologic Oncology Group ancillary study
303
Factors associated with low educational background in uterine cancer patients
355
Impact of smoking on survival among women treated with and without bevacizumab for advanced cervical cancer (CxCA): an NRG Oncology/Gynecologic Oncology Group study
Panel Discussion - Monk
RANDOMIZED PHASE 2 EVALUATION OF BEVACIZUMAB VERSUS BEVACIZUMAB/FOSBRETABULIN IN RECURRENT OVARIAN, TUBAL OR PERITONEAL CARCINOMA: A GYNECOLOGIC ONCOLOGY GROUP STUDY
Association between quality of life and clinical outcome in women with advanced epithelial ovarian cancer receiving chemotherapy with concurrent and maintenance bevacizumab: results from a prospective multicenter phase 3 NRG Oncology/GOG trial
A phase II evaluation of sunitinib (SU11248) in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology / gynecologic oncology group study
Panel Discussion